公司概覽
業務類別 --
業務概覽 RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat severe diseases such as autoimmune diseases, oncology, and ophthalmology. The company has its operations in China and the USA and derives the majority of its revenue from China.
公司地址 58 Middle Beijing Road, Yantai Area of Shandong Pilot Free Trade Zone, Yantai Development Zone, Yantai, CHN
電話號碼 +86 5353573511
傳真號碼 --
公司網頁 https://www.remegen.com
員工數量 3497
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Dr. Jianmin Fang Director -- 28/04/2025
 
董事會成員
董事會 職務 更新日期
Mr. Xianjing Hao Independent Director 28/04/2025
Dr. Liqiang Wang Director 28/04/2025
Mr. Jian Lin Director 28/04/2025
Mr. Weidong Wang Executive Chairman of Board 28/04/2025
Dr. Xiaodi Su Director 28/04/2025
Mr. Yunjin Chen Independent Director 28/04/2025
Mr. Qingkai Wen Director 28/04/2025
Mr. Guobin Huang Independent Director 28/04/2025
Dr. Jianmin Fang Director 28/04/2025
 
所屬ETF (更新日期: 07/03/2026 03:57)
代號 名稱 佔比% 持有日期
BKEMBNY Mellon Emerging Markets Equity ETF0.0003%24/02/2026
EEMXState Street® SPDR®MSCIEMFsslFlRsrvFrETF0.0003%27/02/2026
EMCRXtrackers EM CarbReduc&ClimtImprvs ETF0.0002%24/02/2026
EEMOInvesco S&P Emerging Markets Mom ETF0.0002%27/02/2026
FLAXFranklin FTSE Asia ex Japan ETF0.0002%28/02/2026
SPGMState Street® SPDR® Ptf MSCIGlbStkMktETF0.0001%27/02/2026
REMGSPDR Bloomberg SASB EM ESG Slct ETF0.0001%31/03/2023
ECNSiShares MSCI China Small-Cap ETF<0.000001%24/11/2025
EEMSiShares MSCI Emerging Markets Sm-Cp ETF<0.000001%24/11/2025
EWXState Street® SPDR® S&P® EM Sm Cp ETF<0.000001%22/09/2025
FCAFirst Trust China AlphaDEX® ETF<0.000001%13/01/2026
FPXIFirst Trust International Eq Opps ETF<0.000001%21/12/2025
PIEInvesco DW Emerging Markets Momt ETF<0.000001%02/01/2026
  1   2  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.